Trandolapril/verapamil explained

Type:	combo
Component1:	Trandolapril
Class1:	Calcium channel blocker
Component2:	Verapamil
Class2:	ACE inhibitor
Tradename:	Tarka
Atc Prefix:	C09
Atc Suffix:	BB10
Legal Eu:	Rx-only
Legal Eu Comment:	^[1]
Cas Number:	146994-90-3
Kegg:	D10282

Trandolapril/verapamil (Tarka)^[2] is an oral antihypertensive medication that combines a slow release formulation of verapamil hydrochloride, a calcium channel blocker, and an immediate release formulation of trandolapril, an ACE inhibitor. The patent, held by Abbott Laboratories, expired on February 24, 2015.

This combination medication contains angiotensin-converting enzyme (ACE) inhibitor and calcium channel blocker and is prescribed for high blood pressure.^{[3] [4] [5]}

External links

• Web site: Trandolapril mixture with verapamil hydrochloride . U.S. National Library of Medicine . Drug Information Portal .

Notes and References

1. Web site: Active substance(s): trandolapril / verapamil . List of nationally authorised medicinal products . European Medicines Agency . 29 October 2020 .
2. Web site: Tarka . drugs.com .
3. Reynolds NA, Wagstaff AJ, Keam SJ . Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension . Drugs . 65 . 13 . 1893–1914 . 2005 . 16114984 . 10.2165/00003495-200565130-00011 . 46962760 .
4. García Donaire JA, Ruilope LM . Trandolapril/verapamil combination in hypertensive diabetic patients . Vascular Health and Risk Management . 3 . 1 . 77–82 . 2007 . 17583177 . 1994049 .
5. Sharma SK, Ruggenenti P, Remuzzi G . Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination . Vascular Health and Risk Management . 3 . 4 . 453–465 . 2007 . 17969376 . 2291330 .